Apeloa Pharmaceutical Gets Approval to Conduct Clinical Trials for Semaglutide Injection; Shares Up 3%

MT Newswires12:33

A-shares unusual movement丨Influenza Concept stocks strengthen, Shandong Lukang Pharmaceutical strongly hits the ceiling. Influenza infections in Peking are expected to peak in early January.

On January 3rd, Gelonghui reported that Shandong Lukang Pharmaceutical is strongly hitting the daily limit, Xiangxue Pharmaceutical has risen about 6%, Apeloa Pharmaceutical has increased by about 4%, Shijiazhuang Yiling Pharmaceutical, Zhejiang Hisun Pharmaceutical, and Guangdong Zhongsheng Pharmaceutical have all risen around 2%. In terms of news, the Peking Center for Disease Control and Prevention has made a statement on the recent infectious disease situation, emphasizing that respiratory infectious disease infections are on the rise, with influenza virus infections expected to peak in early January 2025. Furthermore, according to the latest data from the CDC, 66 people across the USA have been confirmed to be infected with the Bird Flu virus. The CDC is closely monitoring signals related to the Bird Flu. (Gelonghui)

Gelonghui Finance10:01

Express News | Apeloa Pharmaceutical: The clinical trial application for semaglutide injection has been approved.

BreakingsJan 2 20:17

The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?

① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.

cls.cnJan 2 16:20

Apeloa Pharmaceutical (000739): A comprehensive Active Pharmaceutical Ingredient leader has formed a funnel-shaped state in its CDMO Business.

As a leader moving from Active Pharmaceutical Ingredient to CDMO and even comprehensive formulation development, Apeloa Pharmaceutical utilizes its foundation in Active Pharmaceutical Ingredient, plans to promote Technology innovation with a Global perspective, and vigorously develops a Global leading pharmaceutical research and production service platform, continuously providing high-quality services.

TianfengDec 18, 2024 18:37

Apeloa Pharmaceutical (000739): The Active Pharmaceutical Ingredient Business is resilient and the formulation and CDMO are expected to accelerate.

Core viewpoint: the company's three main sectors each have highlights in 2024, with the formulation pipeline rapidly expanding and profitability continuously improving. The Active Pharmaceutical Ingredient business shows strong resilience, and capacity construction brings incremental growth. The CDMO project has a good growth trend. R&D investment remains high.

CSCDec 15, 2024 13:17